Skip to content
PubMed This is a summary of 9 peer-reviewed journal articles Updated
Medical Genetics

The Biology of MCADD and How It's Diagnosed

At a Glance

MCADD is an inherited metabolic disorder caused by mutations in the ACADM gene, preventing the body from breaking down medium-chain fats for energy. Diagnosis starts with an elevated C8 marker on a newborn screen and is confirmed through genetic testing.

Understanding the biology of MCADD can help you feel more in control as you manage your child’s health. While the terms can be complex, the core issue is a simple “instruction error” in your child’s DNA that affects how their body produces energy.

The Genetic “Instruction Manual”

Inside almost every cell of the body are genes, which act like an instruction manual. The ACADM gene provides the specific instructions for making an enzyme called MCAD [1][2].

Think of the MCAD enzyme as a specialized pair of “molecular scissors.” Its only job is to cut medium-sized fat molecules into smaller pieces so they can be burned for fuel in the body’s power plants, called mitochondria [3][4]. In a child with MCADD, these scissors are either missing or broken because of a mutation (a typo) in the ACADM gene [5][2].

The Biology: Why Fasting is a Problem

Most of the time, the body runs on glucose (sugar) from food. But when a child hasn’t eaten for a while—like during sleep or when they are sick—the body tries to switch to its backup power source: stored body fat.

  • The Logjam: The body starts breaking down long fat molecules. When they get down to a “medium” size, they reach the MCAD enzyme. Because the enzyme doesn’t work, the process stops abruptly [1][6].
  • Toxic Build-up: These half-processed fats cannot be used for energy. Instead, they begin to build up in the blood and can become toxic to the brain and liver [6][7].
  • Energy Failure: Because the body can’t finish burning the fat, it cannot produce the “backup fuel” (ketones) it needs to keep the brain and heart running safely until the next meal [1].

How MCADD is Diagnosed

Diagnosis usually happens in two stages: the initial screening and the confirmatory testing.

1. The Newborn Screen: Looking for C8

When your baby’s heel was pricked at birth, the lab looked for a specific marker called C8 (octanoylcarnitine) [8]. C8 is essentially a “half-burned” fat molecule that spills into the blood when the MCAD enzyme isn’t working.

  • C8 Levels: An elevation in C8 is the primary “red flag” for MCADD [1].
  • The Ratios: Labs also look at ratios, like C8/C10. These ratios compare the amount of “stuck” medium fats to other fats. Ratios are often more accurate than the C8 level alone in identifying MCADD [8].

2. Confirmatory Testing

If the newborn screen is positive, doctors perform “follow-up” tests to be certain:

  • Plasma Acylcarnitine Profile: A more detailed blood test to confirm the high C8 and ratios [8].
  • Genetic Testing (Molecular Analysis): This is the definitive test. It looks directly at the ACADM gene to identify the specific mutations [9][2].

Understanding Inheritance: Autosomal Recessive

MCADD is an autosomal recessive condition. This is a purely biological event that has nothing to do with anything a parent did or didn’t do during pregnancy [1].

  • Carriers: Most parents of children with MCADD are “carriers.” This means they have one “working” copy of the ACADM gene and one “broken” copy. Carriers are completely healthy and never have symptoms because one working gene is enough to make all the enzyme they need [9].
  • The 25% Chance: When two carriers have a baby, there is a 1 in 4 (25%) chance the baby will inherit the “broken” gene from both parents, resulting in MCADD [1].

Diagnostic Checklist

When you receive your child’s official diagnostic report, ensure it contains the following data points. If any are missing, ask your specialist for a complete report:

  • [ ] C8 Level: The specific concentration of octanoylcarnitine.
  • [ ] C8/C10 Ratio: A key diagnostic marker often used for risk stratification [8].
  • [ ] Genetic Variants: The specific names of the two mutations found in the ACADM gene (for example: c.985A>G) [2].
  • [ ] Interpretation: A clear summary from a board-certified geneticist or metabolic specialist.

Common questions in this guide

What causes MCADD?
MCADD is caused by a mutation in the ACADM gene. This genetic typo prevents the body from making a working MCAD enzyme, which is needed to break down medium-sized fats for energy.
Why is fasting dangerous for a child with MCADD?
When a child fasts, their body tries to use stored fat for energy. Because the MCAD enzyme doesn't work, half-processed fats build up and become toxic, and the body fails to produce the backup energy needed for the brain and heart.
What does an elevated C8 level mean on a newborn screen?
An elevated C8, or octanoylcarnitine, is the primary warning sign for MCADD. It indicates that partially broken-down fat molecules are spilling into the blood because the MCAD enzyme is not processing them properly.
How is MCADD inherited?
Yes, MCADD is an autosomal recessive genetic condition. This means a child must inherit two non-working copies of the ACADM gene, one from each parent, to have the disorder. Parents are typically healthy carriers.
What tests confirm an MCADD diagnosis?
If a newborn screen is positive, doctors use a plasma acylcarnitine profile blood test and genetic testing. Genetic testing looks directly at the ACADM gene to definitively confirm the diagnosis and identify specific mutations.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What were my child's specific C8 and C8/C10 ratio levels?
  2. 2.What are the two specific mutations found in my child's ACADM gene?
  3. 3.Do these specific mutations suggest a 'classical' or 'milder' form of MCADD?
  4. 4.Should our other children or family members be tested for MCADD or carrier status?
  5. 5.Can you explain the results of the 'plasma acylcarnitine profile' versus the initial newborn screen?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (9)
  1. 1

    Medium-chain acyl-coenzyme A dehydrogenase deficiency: Six cases in the Chinese population.

    Li Y, Zhu R, Liu Y, et al.

    Pediatrics international : official journal of the Japan Pediatric Society 2019; (61(6)):551-557 doi:10.1111/ped.13872.

    PMID: 31033143
  2. 2

    Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) precipitating unexpected death in an infant: Report of a case and a brief review of literature.

    Kazemi T, Firgau E, Bunch D, Kahwash SB

    The Malaysian journal of pathology 2022; (44(3)):523-526.

    PMID: 36591720
  3. 3

    A retrospective review of anesthesia and perioperative care in children with medium-chain acyl-CoA dehydrogenase deficiency.

    Allen C, Perkins R, Schwahn B

    Paediatric anaesthesia 2017; (27(1)):60-65 doi:10.1111/pan.13065.

    PMID: 27896927
  4. 4

    Identification of enzymes involved in oxidation of phenylbutyrate.

    Palir N, Ruiter JPN, Wanders RJA, Houtkooper RH

    Journal of lipid research 2017; (58(5)):955-961 doi:10.1194/jlr.M075317.

    PMID: 28283530
  5. 5

    Fatty Acid Beta-Oxidation Disorders: A Brief Review.

    Vishwanath VA

    Annals of neurosciences 2016; (23(1)):51-5 doi:10.1159/000443556.

    PMID: 27536022
  6. 6

    Energetic stress in combination with impaired fatty acid oxidation induces sequestration of CoA and adaptation of CoA metabolism.

    Kiyuna LA, Odendaal C, Singh M, et al.

    The FEBS journal 2026; (293(12)):3565-3587 doi:10.1111/febs.70442.

    PMID: 41652904
  7. 7

    A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net.

    Rossi A, Hoogeveen IJ, Lubout CMA, et al.

    Journal of inherited metabolic disease 2021; (44(5)):1124-1135 doi:10.1002/jimd.12386.

    PMID: 33844307
  8. 8

    A nationwide retrospective observational study of population newborn screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the Netherlands.

    Jager EA, Kuijpers MM, Bosch AM, et al.

    Journal of inherited metabolic disease 2019; (42(5)):890-897 doi:10.1002/jimd.12102.

    PMID: 31012112
  9. 9

    Effective algorithm to differentiate NBS MCADD cases from carriers and non-carriers and an assessment of the utility of the second newborn screen for MCADD.

    Snyder MT, Divin K, Liu N, et al.

    Molecular genetics and metabolism 2025; (145(4)):109183 doi:10.1016/j.ymgme.2025.109183.

    PMID: 40660651

This page explains the biology and diagnosis of MCADD for educational purposes only. Always consult your pediatric metabolic specialist or geneticist to interpret your child's specific newborn screen and genetic test results.

Get notified when new evidence is published on Medium chain acyl-CoA dehydrogenase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.